Loren Alison W, Desai Shashank, Gorman Robert C, Schuchter Lynn M
Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 19104.
Transplantation. 2003 Aug 27;76(4):741-3. doi: 10.1097/01.TP.0000080561.31826.FE.
Donor-derived melanoma is easily transmitted through organ transplants and is highly aggressive in transplant recipients. The best treatment-withdrawal or reduction of immunosuppression-permits tumor rejection but risks allograft rejection. In recipients of nonrenal allografts, the prognosis is particularly grim, with transmission rates and mortality approaching 100%. Retransplantation has been proposed as a possible strategy but has never been performed for a cardiac allograft. This is the first report of cardiac retransplantation and only the second case of retransplantation of any nonrenal organ. Our patient received a heart transplant from a donor found to have occult metastatic melanoma at autopsy. He underwent retransplantation 17 days later. Close clinical and radiographic follow-up reveal no evidence of melanoma 22 months after transplantation. Based on the rapid development of donor-derived melanoma in previous reports, our patient is likely to remain free of donor cancer. Retransplantation and low-dose immunosuppression may have been lifesaving.
供体来源的黑色素瘤很容易通过器官移植传播,并且在移植受者中具有高度侵袭性。最佳治疗方法——停用或减少免疫抑制——可使肿瘤被排斥,但有同种异体移植物被排斥的风险。在非肾同种异体移植受者中,预后尤其严峻,传播率和死亡率接近100%。再次移植已被提议作为一种可能的策略,但从未用于心脏同种异体移植。这是心脏再次移植的首例报告,也是任何非肾器官再次移植的第二例。我们的患者接受了一名尸检发现患有隐匿性转移性黑色素瘤的供体的心脏移植。17天后他接受了再次移植。移植22个月后的密切临床和影像学随访未发现黑色素瘤迹象。基于先前报告中供体来源黑色素瘤的快速发展情况,我们的患者可能不会患供体癌症。再次移植和低剂量免疫抑制可能挽救了患者的生命。